Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study
Keywords:
Adverse drug event
Hepatocellular carcinoma
Immunotherapy
Nivolumab
PD-1 inhibitor
Note:
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Citation:
Julien, K. (Karen); Leung, H.T. (Hiu Tung); Fuertes, C. (Carmen); et al. "Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study". The Oncologist. 25 (10), 2020, e1532 - e1540
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.